SOURCE: Vicor Technologies, Inc.

Vicor Technologies, Inc.

December 03, 2009 08:30 ET

Heart Rate Variability Gains Popularity as Cost-Effective Diagnostic

Vicor's PD2i® Nonlinear Algorithm Measures Heart Rate Variability, Clinically Proven Most Accurate Diagnostic for Risk Stratifying Sudden Cardiac Death, Autonomic Dysfunction, and Trauma

BOCA RATON, FL--(Marketwire - December 3, 2009) - According to Dr. Daniel Weiss, a recent study of heart rate autonomic markers, and cardiac mortality published in the November issue of Heart Rhythm provides additional support for the usefulness of heart rate variability as a diagnostic for identifying dysfunction (neuropathy in diabetics and others) and cardiovascular mortality, including fatal arrhythmia or sudden cardiac death. Dr. Weiss is a cardiologist and Chief Medical Officer of Vicor Technologies. Vicor Technologies, Inc. (OTCBB: VCRT) is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

"As the national debate on how to cut healthcare spending continues, diagnostics that enable inexpensive, accurate, and early identification of disease states in at-risk populations (more than a) 12 million at-risk cardiac patients, b) 23.7 million diabetics, and c) 38 million trauma incidents) -- prior to costly treatments for advanced disease or inaccurate identification -- are garnering increased attention. While awareness of HRV's potential to serve as a cost-effective diagnostic for numerous disease states has existed for quite some time, only recently has HRV, which is collected in a simple ECG, become the diagnostic of choice; the challenge is accurately unlocking the information contained in HRV to obtain a useful diagnosis," stated Dr. Weiss.

"In multiple trials comparing the efficacy of various tools in measuring HRV for diagnostic purposes, Vicor's PD2i® nonlinear algorithm has consistently proven itself to be the most consistently accurate diagnostic for identifying those at risk of sudden cardiac death and autonomic dysfunction, as well as trauma victims in need of lifesaving intervention. As such, Vicor's PD2i® nonlinear algorithm effectively lowers healthcare spending by providing an inexpensive to use diagnostic that enables accurate early diagnosis of conditions before they advance to costly disease states, and also prevents the exorbitant costs associated with inaccurate diagnosis and resulting unnecessary, ineffective treatment," Dr. Weiss concluded.

About Daniel N. Weiss, MD, FACC

Dr. Weiss has extensive experience in the practice of cardiology and electrophysiology. In addition to serving as Vicor's Chief Medical Officer, Dr. Weiss is a partner with Florida Arrythmia Consultants, and has served as a consultant to Fortune 500 medical device manufacturers such as Medtronics, St. Jude Medical, and Guidant. He also served as a clinical investigator on the two most important clinical trials involving the study of ICDs and SCD: the MADIT-II (MultiCenter Automatic Defibrillator Implantation Trial) and SCD HeFT (Sudden Cardiac Death Heart Failure Trial). He is a former director of the cardiac physiology laboratory at Boca Raton Hospital. Dr. Weiss earned his MD (with Distinction in Research) at Mount Sinai School of Medicine, from which he also received the Nathan A. Setz Award for Research in Cardiovascular and Renal Disease. He holds a BSE, cum laude, in Electrical Engineering and Computer Science from Princeton University.

About Vicor Technologies, Inc.

Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research, risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™(Cardiac Analyzer), our ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies, included but not limited to our ASP distribution model for the PD2i Analyzer™; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 09-23

Contact Information